Please login to the form below

Not currently logged in
Email:
Password:

Xiidra

This page shows the latest Xiidra news and features for those working in and with pharma, biotech and healthcare.

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe. Analysts predict Xiidra could become a $1bn product. ... The Anglo-Irish company claimed approval for first-in-class LFA-1 antagonist lifitegrast under the Xiidra brand name in the US last year at the

Latest news

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast). ... That is a different mechanism of action to current drugs

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    Shire launches dry eye drug Xiidra in US. Sparks rivalry with Allergan’ s blockbuster Restasis as first new dry eye treatment in 13 years. ... That gives Xiidra a broader label than Restasis (cyclosporine) that analysts suggest could catapult it to

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    FDA finally approves Shire’ s potential blockbuster Xiidra. Dry eye disease treatment wins US licence. ... Xiidra is tipped to be a $1bn product and is one of the stars of the Ireland-based manufacturer's pipeline.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics